Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Shares Issued (2019 - 2025)

Pulmonx (LUNG) has disclosed Shares Issued for 6 consecutive years, with $5000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Shares Issued fell 82.14% to $5000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $253000.0, a 47.09% increase, with the full-year FY2024 number at $218000.0, down 29.68% from a year prior.
  • Shares Issued was $5000.0 for Q3 2025 at Pulmonx, down from $28000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $1.3 million in Q2 2021 to a low of $5000.0 in Q3 2025.
  • A 5-year average of $167684.2 and a median of $72000.0 in 2022 define the central range for Shares Issued.
  • Biggest YoY gain for Shares Issued was 982.35% in 2021; the steepest drop was 96.95% in 2021.
  • Pulmonx's Shares Issued stood at $150000.0 in 2021, then increased by 26.67% to $190000.0 in 2022, then plummeted by 66.32% to $64000.0 in 2023, then skyrocketed by 71.88% to $110000.0 in 2024, then crashed by 95.45% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for LUNG's Shares Issued are $5000.0 (Q3 2025), $28000.0 (Q2 2025), and $110000.0 (Q1 2025).